What an incredible few days at Jefferies & London Life Science Week! 🎉 A huge thank you to Jefferies, the BioIndustry Association (BIA), MedCity, and London & Partners for hosting this goliath event. It gets bigger, better and more impactful every year, and we’re proud to be part of it. We are glad so many […]
You have probably already seen the news: not one but two major European life science funds have closed in the last week – collectively raising a massive €1.15 billion! Last Friday (November 14), leading European life sciences venture capital firm Medicxi announced it had closed its €500 million Medicxi V fund. And on Monday, (November […]
The big buzz around AI in healthcare is the potential it holds to identify and even create new drugs. “AI drug discovery” is the great new hope. And – despite critics awkwardly pointing out that no AI-generated drugs have yet been approved by any regulator, and vanishing few appear to be close to that finishing […]
Firstly, congratulations to the team at Verona Pharma on their incredible $10bn dollar deal with Merck! And to Actithera on their oversubscribed $75.5M Series A – a great achievement in the current market. Huge congratulations also go to the incomparable Clive Cookson on receiving the Lifetime Achievement Award at the Association of British Science Writers […]
Challenges to pharma charging premium prices for branded drugs are not new. Think of President Biden’s attempts to drive down prices with the Inflation Reduction Act. Or the UK’s strategy of capping the price the NHS pays for branded medicines with its VPAG rebate scheme. But President Trump’s “most favoured nation” policy – which attempts […]
